Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Cyclacel Pharmaceuticals, Inc. Form 4 February 21, 2008

February 2	1, 2008									
FOR	ЛД							OMB A	PPROVA	L
	VI – UNITED	STATES			AND EXCHAN(, D.C. 20549	GE COMMISS	ION	OMB Number:	3235-	0287
	Check this box							Expires:	Januar	•
subject Section	if no longer subject to Section 16. Form 4 or							Estimated average burden hours per		2005 0.5
Form 5 obligati may co <i>See</i> Inst 1(b).	ions Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1040								0.0
Print or Type	e Responses)									
1. Name and McVie Joh	Address of Reporting In Gordon	2. Issuer Name and Ticker or Trading Symbol Cyclacel Pharmaceuticals, Inc.			5. Relationsl Issuer	5. Relationship of Reporting Person(s) to Issuer				
			[CYCC		iceuticais, file.	((Check	all applicable	e)	
(Last)	(First) (IIII/Dav/Ical)			ive title 10% Owner Other (specify		
200 CONN 1500	NELL DRIVE, SU	ITE	02/19/2	-		below)		below)		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			Applicable Li _X_ Form file	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
BERKELE	EY HEIGHTS, NJ	07922				Form file Person	d by Mo	ore than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Securitie	es Acquired, Dispos	sed of,	or Beneficia	lly Ownee	b
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ransaction Date 2A. Deemed nth/Day/Year) Execution Date, if any		TransactionAcquired (A) or Sec		5. Amount of Securities Beneficially	Fc	Ownership orm: Direct) or Indirect	7. Nature Indirect Beneficia	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 8) (Instr. 3, 4 and 5)

Code V Amount (D) Price

(A)

or

Owned

Following

Transaction(s)

(Instr. 3 and 4)

Reported

Persons who respond to the collection of

information contained in this form are not

required to respond unless the form displays a currently valid OMB control

(I)

(Instr. 4)

Ownership

(Instr. 4)

SEC 1474

(9-02)

(Month/Day/Year)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

number.

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day/Yea	;)	(Instr. 3 and 4	4)
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Share
Option	\$ 4.31	02/19/2008		А	25,000	02/19/2008(1)	02/19/2018	Common Stock	25,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
McVie John Gordon 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS, NJ 07922	Х					
Signatures						

/s/ John Gordon McVie	02/20/2008			
**Signature of Reporting	Date			

Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options will vest ratably over a 48-month period.

(2) The options were granted to Professor McVie for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.